Skip to main content
SpringerLink
Log in

The UK NICE has issued guidance to the NHS in England and Wales on the use of cinacalcet for the treatment of secondary hyperparathyroidism.

  • Guideline
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. National Institute for Health and Clinical Excellence.Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology Appraisal Guidance: 1-28, No. 117, Jan 2007. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The UK NICE has issued guidance to the NHS in England and Wales on the use of cinacalcet for the treatment of secondary hyperparathyroidism.. Pharmacoecon. Outcomes News 521, 3 (2007). https://doi.org/10.2165/00151234-200705210-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705210-00006

Keywords

Search

Navigation